New insights into the pathogenesis of IgA nephropathy

被引:0
作者
See Cheng Yeo
Chee Kay Cheung
Jonathan Barratt
机构
[1] Tan Tock Seng Hospital,Department of Renal Medicine
[2] University of Leicester,Department of Infection, Immunity and Inflammation
[3] Leicester General Hospital,The John Walls Renal Unit
来源
Pediatric Nephrology | 2018年 / 33卷
关键词
IgA nephropathy; Pathogenesis; IgA1; -galactosylation; Immune complexes;
D O I
暂无
中图分类号
学科分类号
摘要
IgA nephropathy is the most common form of glomerulonephritis in many parts of the world and remains an important cause of end-stage renal disease. Current evidence suggests that IgA nephropathy is not due to a single pathogenic insult, but rather the result of multiple sequential pathogenic “hits”. An abnormally increased level of circulating poorly O-galactosylated IgA1 and the production of O-glycan-specific antibodies leads to the formation of IgA1-containing immune complexes, and their subsequent mesangial deposition results in inflammation and glomerular injury. While this general framework has formed the foundation of our current understanding of the pathogenesis of IgA nephropathy, much work is ongoing to try to precisely define the genetic, epigenetic, immunological, and molecular basis of IgA nephropathy. In particular, the precise origin of poorly O-galactosylated IgA1 and the inciting factors for the production of O-glycan-specific antibodies continue to be intensely evaluated. The mechanisms responsible for mesangial IgA1 deposition and subsequent renal injury also remain incompletely understood. In this review, we summarize the current understanding of the key steps involved in the pathogenesis of IgA nephropathy. It is hoped that further advances in our understanding of this common glomerulonephritis will lead to novel diagnostic and prognostic biomarkers, and targeted therapies to ameliorate disease progression.
引用
收藏
页码:763 / 777
页数:14
相关论文
共 1112 条
[81]  
Iwase H(1997)Toll-like receptor 9 stimulation induces aberrant expression of a proliferation-inducing ligand by tonsillar germinal center B cells in IgA nephropathy J Am Soc Nephrol 8 1579-1587
[82]  
Shinzato T(1997)A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction Kidney Int 52 3278-3284
[83]  
Kobayashi Y(2014)Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling PLoS One 9 1791-1797
[84]  
Maeda K(2012)Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells J Am Soc Nephrol 23 82-86
[85]  
Coppo R(2016)In vitro-generated immune complexes containing galactose-deficient IgA1 stimulate proliferation of mesangial cells J Am Soc Nephrol 27 793-806
[86]  
Amore A(2010)Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity J Am Soc Nephrol 21 148-152
[87]  
Xu LX(2005)Evidence for involvement of IgA1 hinge glycopeptide in the IgA1-IgA1 interaction in IgA nephropathy Nefrologia 25 203-211
[88]  
Zhao MH(2012)Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG J Exp Med 209 815-822
[89]  
Woof JM(2007)A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases Contrib Nephrol 157 514-521
[90]  
Russell MW(2007)Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy Blood 109 1281-1287